| HOME >> BIOLOGY >> TECHNOLOGY |
of related debt during the six months ended June 30, 2007, in conjunction
with our financing arrangements.
(g) A $1.7 million net realized foreign currency loss associated with a
cash escrow established in connection with the acquisition of BBI Holdings
Plc.
(h) A $1.9 million foreign currency gain realized on the settlement of
intercompany notes.
(i) Tax effect on adjustments as discussed above in notes (b), (c), (d),
(e), (f), (g) and (h).
(j) For the six months ended June 30, 2008 and 2007, potential dilutive
shares were not used in the calculation of diluted net loss per common
share under GAAP because inclusion thereof would be antidilutive.
(k) Included in the weighted average diluted common shares for the
calculation of net income per common share for the three months ended June
30, 2008, on an adjusted cash basis, are dilutive shares consisting of
2,344,000 common stock equivalent shares from the potential exercise of
stock options and warrants and potential dilutive shares consisting of
3,411,000 common stock equivalent shares from the potential conversion of
convertible debt securities. The net income per diluted share calculation
for the six months ended June 30, 2008, on an adjusted cash basis,
includes the add back of interest expense related to the convertible debt
of $1.5 million resulting in net income available to common stockholders
of $70.2 million. Potential dilutive shares consisting of 3,004,000 common
stock equivalent shares from the potential conversion of Series B
convertible preferred stock for the six months ended June 30, 2008 were
not used in the calculation of diluted net income per common share, on an
adjusted cash basis, because inclusion thereof would be antidilutive.
(l) Included in the weighted average diluted common shares for the
calculation of ne
'/>"/>
| SOURCE Inverness Medical Innovations, Inc. Copyright©2008 PR Newswire. All rights reserved |